Home » Stocks » AlloVir

AlloVir, Inc. (ALVR)

Stock Price: $37.38 USD -0.33 (-0.88%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.34B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 62.67M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $37.38
Previous Close $37.71
Change ($) -0.33
Change (%) -0.88%
Day's Open 37.64
Day's Range 36.94 - 41.97
Day's Volume 301,875
52-Week Range 18.15 - 45.28

More Stats

Market Cap 2.34B
Enterprise Value 2.24B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 62.67M
Float 1.75M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 17.86
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 104.73M
Net Cash / Share 1.67
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-85.46%-
Gross Profit0.171.14
Operating Income-26.70-3.60
Net Income-23.84-2.43
Shares Outstanding1.920.30
Earnings Per Share-12.44-25.07
Operating Cash Flow-20.161.94
Capital Expenditures-0.34-
Free Cash Flow-20.491.94
Cash & Equivalents12624.96
Total Debt11.76-
Net Cash / Debt11424.96
Book Value-51.50-30.62
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AlloVir, Inc.
Country United States
Employees 20
CEO David L. Hallal

Stock Information

Ticker Symbol ALVR
Stock Exchange NASDAQ
Sector Technology
Industry Wireless Communications
Unique Identifier NASDAQ: ALVR
IPO Date July 30, 2020


Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.